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One of the enzymes responsible for nitric oxide (NO) production in neutrophils is the inducible nitric oxide synthase 
(iNOS). Changes in its expression may result from the activation of different signaling pathways, including MAPK, which 
lead to activation of various genes, including DUSP genes. DUSP induce the negative feedback loop leading to MAPK 
deactivation through their phosphorylation. Our study assessed the role of DUSP1, DUSP10 and DUSP16 with the 
participation of MAPK in the iNOS-dependent NO production by neutrophils exposed to xenobiotic, N-nitrosodimethylamine 
(NDMA). The obtained results suggest that N-nitrosodimethylamine enhances the expression of all tested proteins (except 
DUSP10) in the cytoplasmic and nuclear fractions of neutrophils. The JNK pathway inhibition resulted in an extenuation of 
iNOS, phospho-p38 and DUSP10 expression in the cytoplasmic fraction and DUSP1 expression in the nuclear fraction of 
neutrophils. Inhibition of the p38 pathway led to a lower expression of iNOS, DUSP16 and DUSP10 in the cytoplasmic 
fraction. No changes in the phospho-JNK and DUSP1 expressions were observed. With the results of this study we can 
conclude that DUSP are positive regulators of MAP kinases in NDMA-induced signaling pathway which lead to modulation 
of iNOS-dependent NO production in human neutrophils. 
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One of the enzymes responsible to produce nitric oxide 
(NO) in immune system cells is an inducible nitric 
oxide synthase (iNOS)1-3. Activation of different 
intracellular signaling pathways, including MAPK, 
cause changes in iNOS expression, in both, 
pathological and physiological states4,5. The MAP-
kinase (MAPK) signaling pathway is a family of 
serine-threonine kinases: JNK, p38, ERK1/2 and 
ERK5. All of MAP kinases contain the Thr-X-Tyr 
(TXY) motif, whose phosphorylation leads to their 
activation6,7. 
The activated MAP kinases, by phosphorylation of 
transcription factors lead to activation of several genes, 
including those coding for kinase phosphatases 
(MKPs)7,8. MKPs induce the negative feedback loop 
leading to the inactivation of MAP kinases through 
their phosphorylation. MKPs phosphatases may also 
occur in the cells with low level expression9-11. Among 
the MKPs proteins, three phosphatase families are 
distinguished based on their active sites: tyrosine 
phosphatases (HePTP/LC-PTP, PTP-SL/STEP), serine 
and threonine phosphatases (PP1, PP2A, PP2B) and 
tyrosine, and serine and threonine phosphatases 
(DUSP)12,13.  
DUSP proteins exhibit varying substrate specificity 
MAPK, intracellular location and different action time. 
Presence of 10 out of 13 identified MKPs was 
determined in PMNs. p38 and JNK kinase inactivation 
in these cells primarily involves three phosphatases, 
DUSP1 (MKP-1; found in the nucleus), DUSP10 
(MKP-5; located in the nucleus and cytoplasm) and 
DUSP16 (MKP-7; occurring in the cytoplasm)10,14-16. 
Studies have demonstrated that DUSP phosphatases 
not only activate MAP kinases, but also can lead to 
elevated selective activity of a particular kinase or 
enhance their activity through interaction with these 
kinases9. Their significant role was determined for 
production of cytokines and control of iNOS 
expression induction in cells17. 
Further, data indicate that certain mediators, 
including TNF and IL-1, through specific kinases may 
activate protein phosphatases, thus leading to further 
activation of MAPK cascade9,18. Earlier, we 
demonstrated that N-nitrosodimethylamine (NDMA) 
increases iNOS expression and nitric oxide production 
in human neutrophils through parallel activation of 








action, activates the p38 pathway more efficiently. On 
the other hand, a prolonged exposure to this xenobiotic 
leads to stronger activation of the JNK pathway than 
the p38 pathway in PMNs19,20. Induction of iNOS 
expression and NO production in these cells is not 
directly linked to the EK1/2 and ERK5 kinases. Studies 
have also demonstrated interactions between p38 and 
JNK kinases and ERK1/2 and p38 kinase in regulation 
of iNOS-dependent NO production in polymorphonuclear 
leukocytes (PMN) exposed to NDMA21,22. 
The literature is silent on the contribution of DUSP 
phosphatases in regulation of iNOS-dependent NO 
production in leucocytes exposed to the NDMA. 
Because we have been studying the role of the 
signaling pathway induced by NDMA in human 
neutrophils in iNOS-dependent NO production, we 
have drawn a compelling conclusion that “all pathways 
lead to MAP kinases”. Since the MAP kinase 
activation leads to the activation of transcription 
factors, including AP-1 and NF-B, as well as STAT 
proteins6-8, assessment of the expression of 
transcription factors, including STAT1 and STAT3 
induced by JNK and p38 kinases in PMN exposed to 
NDMA, will enable better understanding of the basics 
of molecular mechanism of this xenobiotic effect on 
the functions of the tested leukocyte population linked 
to the synthesis and release of NO. Here, we tried to 
evaluate of DUSP protein activity involved in the 
iNOS-dependent NO production in neutrophils 
exposed to the effect of NDMA. Also, we estimated the 
role of individual DUSP phosphatases in the activation 
of MAP kinases involved in NO production by 
neutrophils exposed to the xenobiotic (Fig. 1). 
 
Materials and Methods 
 
Reagents 
NDMA, Griess reagent and BCIP/NBT Liquid 
substrate system were purchased from Sigma 
(Steinheim, Germany). SB203580 and SP600125 were 
obtained from Calbiochem (San Diego, CA). Laemmli 
buffer, Tris-Buffered Saline (TBS)/Caseine buffer and 
TBS-T [containing: Tris-Buffered Saline and Tween 
20] were purchased from BioRad Laboratories 
(Hercules, CA).  
Antibodies 
Monoclonal mouse antibodies against iNOS, 
phospho-p38, DUSP10 and β-actin, polyclonal goat 
antibodies against phospho-JNK, DUSP16, phospho-
STAT1 and phospho-STAT3 protein, as well as 
polyclonal rabbit antibodies against DUSP-1 were 
purchased from Santa Cruz Biotechnology 
(Heidelberg, Germany). Goat anti-mouse IgG antibody 
conjugated with alkaline phosphatase (AP), donkey 
anti-goat IgG antibody conjugated with alkaline 
phosphatase and goat anti-rabbit IgG antibody 
conjugated with alkaline phosphatase were obtained 
from Vector Laboratories (Burlingame, CA). 
Monoclonal mouse antibody against the Poly(ADP-
ribose)polymerase (PARP-1) was purchased from 
Calbiochem. 
Isolation and incubation of PMNs 
The study involved a group of 20 healthy (age 20-
50 years) volunteer blood donors from the Regional 
Centre for Transfusion Medicine (Bialystok, Poland). 
Males were chosen to avoid possible influences due to 
endogenous hormones on the experimental findings. 
The Ethics Committee of the Medical University of 
Bialystok (R-I-002/41/2015) approved this study. All 
persons gave written informed consent prior to blood 
donations. 
PMNs were isolated from heparinized (10 U/mL - 
Heparin, Polfa, Lodz, Poland) whole blood by density 
centrifugation using Gradisol G gradient 1.115 g/mL 
(Polfa)23. This method enables simultaneous separation of 




Fig. 1 — iNOS signaling 
 




91% PMN) and PBMC (containing 94% lymphocytes). 
The purity of isolated PMN was determined by 
MayGrunewald-Giemsa. Sera were obtained from blood 
samples collected without anticoagulation agents. 
 
PMNs were suspended at a concentration of 5106 
cells/mL in Hanks’ Balanced Salt Solution (Invitrogen, 
Carlsbad, CA) containing the subject’s own serum 
(7.4%, 20/270 µL), 100 U penicillin/mL, and 50 ng 
streptomycin/mL (Polfa Trachomin SA, Warsaw, 
Poland). The cells (200 µL aliquots) were then placed 
into wells of microplates (Microtest III-Falcon, BD 
Biosciences, Bedford, MA) and incubated for 2 h at 
37C in a 5% CO2 incubator (NuaireTM US Autoflow, 
Plymouth, MN). PMN in the wells were then treated 
with 20 µL NDMA to attain a final concentration of 
0.74 g NDMA/L in the well; control wells received 
vehicle only. Dose of NDMA was selected based on 
preliminary studies that determined the cytotoxic 
effects of NDMA on these cell types24; metabolic 
activity was decreased in the leukocytes only among 
cells incubated with ≥0.74 g NDMA/L. The PMNs 
were then cultured a further 2 h before culture 
supernatants were collected. Assessments of viability 
(via trypan blue exclusion) showed that PMNs were 
still >93% viable after the treatment. 
 
Phospho-p38 and phospho-JNK expressions are 
markers of p38 and JNK pathways activation. 
Similarly, JAK/STAT pathway activation manifests by 
a presence of the phospho-STAT1 and phospho-
STAT3 proteins. 
In order to determine the role of MAP kinase in the 
DUSP family proteins and STAT engaged in regulation 
of iNOS expression in PMN exposed to NDMA, 
selective inhibitors of particular pathways were used. 
In these studies, cells were pre-incubated with: 40 μM 
SP600125, a selective JNK pathway inhibitor25 or with 
40 μM SB203580 - a selective p38 pathway inhibitor26 
for 1 h before the addition of NDMA. Preliminary 
studies showed that the presence of any of the 
inhibitors did not affect the cell viability. 
Protein isolation and Western blot analyses 
Cytoplasmic and nuclear extracts from PMNs 
(3106 cells total/sample) were prepared using 
NucBusterTM Protein Extraction Kit (Calbiochem). 
Step-wise extraction delivered two distinct cellular 
protein fractions: cytoplasmic and nuclear. The 
concentration of protein in each was determined with a 
QubitTM Protein Assay Kit (Invitrogen). An antibody 
against PARP-1 (1:5000) and against β-actin (1:100) 
were used as an internal control within the nuclear and 
cytoplasmic fractions, respectively. 
The extracts were suspended in Laemmli buffer, 
loaded at 20 µg/well, and then electrophoresed over a 
4% stacking and a 10% separating SDS-PAGE gel. The 
resolved proteins were electrotransferred onto 0.45-m 
pore-size nitrocellulose membranes (BioRad) then 
blocked with Tris-Buffered Saline (TBS)/Caseine 
buffer, washed with TBS-T (TBS with 0.05% Tween-20), 
and incubated with QentixTM Western Blot Signal 
Enhancer (Thermo Fisher Scientific, Rockford, IL). 
The membranes were then incubated for 10 min at room 
temperature (21C) in SNAP (Protein Detection System; 
Millipore, Billerica, MA) with 1:100 dilutions of 
primary monoclonal antibody against iNOS, phospho-
p38, DUSP10 or primary polyclonal antibodies against 
phospho-JNK, DUSP16, phospho-STAT1 and 
phospho-STAT3 or DUSP1. After washing with 0.1% 
TBS-T, the membrane was incubated at room 
temperature with alkaline phosphatase anti-mouse IgG 
Ab, anti-rabbit IgG Ab or anti-goat IgG Ab (1:200). 
Immunoreactive bands were then visualized using 
BCIP/NBT Liquid substrate system; intensities were 
determined using ImageJ software (Bethesda, MD) and 
reported as Arbitrary Units (A.U.). 
 
Assay for nitrite production 
Synthesis of NO was determined by an assay of the 
culture supernatant for nitrite, a stable reaction product 
of NO with molecular oxygen. Total NO concentration 
is commonly determined as a sum of the nitrite and 
nitrate concentrations present. NO production by 
PMNs were determined using an indirect method based 
on measurement of nitrite concentration in culture 
supernatants according to a Griess reaction27. In the 
analyzed samples, nitrate was reduced to nitrate in the 
presence of cadmium, and then converted to nitric acid 
that yielded a color reaction with Griess reagent. Nitrite 
concentrations were determined by spectrophotometric 
analysis at 540 nm with extrapolation from a standard 
curve prepared in parallel. Nitric oxide products were 
expressed as µM (106 cells in 270 µL supernatant). 
Statistical analysis 
Results were analyzed using Statistica version 9.1. 
(StatSoft, Inc., Tulsa, OK). Data distribution normality 
were determined using a Kolmogorov-Smirnov test. 
Since data were not normally distributed, for comparison 
of variations between assayed groups, Mann-Whitney U 
non-parametric tests were applied to unrelated results. 
A p-value ≤0.05 was accepted as statistically 
significant. All data are presented as mean ± SE. 






Total NO concentration in PMN supernatants  
Exposure of neutrophils to N-nitrosodimethylamine 
confirmed earlier observations which demonstrated 
enhanced release of nitric oxide in comparison to cells 
incubated without this xenobiotic. In order to confirm 
contribution of the examined MAP kinases: JNK and 
p38 in the iNOS-dependent nitric oxide production by 
neutrophils exposed to NDMA, its concentration in the 
presence of selective inhibitors of individual kinases 
was determined. We found in the supernatants of 
neutrophils, which were preincubated with the JNK 
and p38 pathway inhibitors, and treated with NDMA, 
lower concentrations of total NO in comparison to the 
cellular supernatants without an inhibitor (Table 1). 
 
Expression of iNOS, phospho-JNK, phospho-p38, DUSP1, DUSP10, 
DUSP16, phospho-STAT1 and phospho-STAT3 in PMNs 
Exposure of neutrophils to N-nitrosodimethylamine 
led to a parallel increase of the expression of iNOS, 
phospho-p38 and phospho-JNK in the cytoplasmic 
fraction in comparison to the cells incubated without 
the xenobiotic (Fig. 2). Moreover, an increased 
DUSP16 expression was determined in the 
cytoplasmic fraction and DUSP1 in the nuclear fraction 
of these cells. However, no changes in DUSP10 
expression were observed for both neutrophil fractions 
(Fig. 2). Moreover, neutrophil incubation with NDMA 
demonstrated higher expression of phospho-STAT1 
and phospho-STAT3 in both cytoplasmic and nuclear 
fractions. The phospho-STAT1 and phospho-STAT3 
expression in the nuclear fraction of PMN exposed to 
NDMA was higher in comparison to expression of 
these proteins in the cytoplasmic fraction (Fig. 3). 
Experiments with the inhibitors of kinases were 
performed to establish the role of MAP kinases (JNK 
and p38) in induction of the studied DUSP proteins and 
STAT transcription factors. Pre-incubation with  
the JNK pathway inhibitor (SP600125) confirmed our  
 
Table 1 — Concentrations of total NO (μM/106 cells (in 270 μL supernatant)) from PMNs 
PMNsx ±SE PMNs+NDMAx ±SE PMNs+ SP600125+NDMAx ±SE PMNs+ SB203580+NDMAx ±SE 
10.83 ±3.39 21.31* ±4.78 12.29a ±4.75 11.45b ±4.02 
[PMNs were treated with or without SP600125 (40 μM) or SB203580 (40 μM) for 1 h before addition of NDMA (0.74 μg/μL). Two hours 
after addition of NDMA, the nitrite concentrations were measured as a marker of NO production. * Value significantly different between 
cells without and with NDMA (P <0.05); a value significantly different between cells treated with NDMA but pre-incubated without or 
with the inhibitor SP600125 (P <0.05). b value significantly different between cells treated with NDMA but pre-incubated without or with 
the inhibitor SB203580 (P <0.05). Data are expressed as μM/106 cells (in 270 μL supernatant) and are shown as mean  





Fig. 2 — Expressions of iNOS, fosfo-JNK, fosfo-p38, DUSP1, DUSP1 and DUSP16 in PMNs. [PMNs were treated with or without 
SP600125 SB203580 (40 μM) or SB203580 (40 μM) for 1 h before addition of NDMA (0.74 μg/μL). The cytoplasmic and nuclear fractions 
obtained from those cells were used to detect iNOS, fosfo-JNK, fosfo-p38, DUSP1, DUSP10 and DUSP16 protein levels by western 
blotting. The results shown are representative of five independent experiments. Band intensity was quantified using ImageJ software and 
expressed in arbitrary units (A.U.). Data shown are mean (± SE) of five independent experiments. * Value significantly different between 
cells without and with NDMA (P <0.05); a value significantly different between cells treated with NDMA but pre-incubated without or 
with the inhibitor SP600125 (P <0.05); and b value significantly different between cells treated with NDMA but pre-incubated without or 
with the inhibitor SB203580 (P <0.05)] 
 




earlier results that decreased expression of iNOS 
phospho-p38 in the cytoplasmic fraction of neutrophils 
exposed to NDMA in comparison to cells incubated 
without the inhibitor20. Decreased DUSP10 expression 
was determined in the cytoplasmic fraction and DUSP1 
in the nuclear fraction. No changes in the expression of 
DUSP16 in the cytoplasmic fraction and DUSP10 in 
the nuclear fraction were observed (Fig. 2). The use of 
the JNK pathway inhibitor (SP600125) in the 
cytoplasmic fraction of PMN exposed to NDMA 
increased expression of phospho-STAT1 and phospho-
STAT3 in comparison to the cells without the inhibitor. 
No changes in the expression of these proteins in the 
nuclear fraction were observed (Fig. 3). In the presence 
of the p38 pathway inhibitor (SB203580), a decreased 
iNOS expression in the cytoplasmic fraction of PMN 
exposed to NDMA was confirmed20. No changes were 
found in phospho-JNK expression in the cytoplasmic 
fraction, the same as DUSP1 and DUSP10 in the 
nuclear fraction of neutrophils in comparison to their 
expression in the cells incubated without the inhibitor. 
However, lower expression of DUSP16 and DUSP10 
in the cytoplasmic fraction was demonstrated (Fig. 2). 
Inhibition of the p38 pathway decreased expression of 
phospho-STAT1 and phospho-STAT3 in the 
cytoplasmic fraction of neutrophils exposed to NDMA 
in comparison to cells without the inhibitor. Moreover, 
decreased expression of phospho-STAT1 in the 
nuclear fraction was observed in the tested cells. No 
changes in the expression of phospho-STAT3 were 
observed in this fraction (Fig. 3). 
 
Discussion 
The presented results and our earlier observations 
confirm the significant effect of N-nitrosodimethyl-
amine (NDMA) on the iNOS expression and NO 
production by human neutrophils19. NDMA is a 
compound with high carcinogenic, mutagenic and 
teratogenic potentials. Therefore, the highest allowable 
concentration of NDMA in drinking water should not 
exceed 0.7 ng/L. A slight excess of this concentration 
with prolonged exposure time may be considered as a 
low-dose, chronic exposure to NDMA, which are 
manifested by primarily cancerous changes of different 
organs, particularly of the liver28,29. Most information 
about the direct, acute effect of NDMA is mainly based 
on experimental studies. Data obtained from various 
studies demonstrate that NDMA cytotoxicity toward 
hepatocyte cultures are exhibited at the concentration 
of 0.1 mM, and for the cells of kidneys and lungs a 
range of concentration 3-50 g/mL30,31. The tested 
cells, neutrophils, have the shortest life span among the 
cells of the body system. Every day, marrow releases 




Fig 3 — Expressions of phospho-STAT1 and phospho-STAT3 in PMNs. [PMNs were treated with or without SP600125 SB203580 (40 
μM) or SB203580 (40 μM) for 1 h before addition of NDMA (0.74 μg/μL). The cytoplasmic and nuclear fractions obtained from those 
cells were used to detect phospho-STAT1 and phospho-STAT3 protein levels by western blotting. The results shown are representative of 
five independent experiments. Band intensity was quantified using ImageJ software and expressed in arbitrary units (A.U.). Data shown 
are mean (± SE) of five independent experiments. * Value significantly different between cells without and with NDMA (P <0.05); a value 
significantly different between cells treated with NDMA but pre-incubated without or with the inhibitor SP600125 (P <0.05); b value 
significantly different between cells treated with NDMA but pre-incubated without or with the inhibitor SB203580 (P <0.05); and c value 
significantly different between cytoplasmic and nuclear fractions (P <0.05)] 
 




of body wt., where they remain for 6-12 h32. Therefore, 
in order to achieve the intensified effect of NDMA on 
these cells in vivo, we used higher concentration of the 
xenobiotic in the study24. Our results for the first time 
demonstrated that the N-nitrosodimethylamine leads to 
activation of DUSP1 and DUSP16 in human 
neutrophils. 
Following observations of different authors, 
expression of MKPs occurs at a lower level in non-
stimulated cells33. This is further confirmed by the 
results of our study, on neutrophils not exposed to the 
xenobiotic, which demonstrated low DUSP1 
expression in the nuclear fraction and DUSP16 in the 
cytoplasmic fraction. In the light of earlier 
observations that the exposition of human PMNs to  
N-nitrosodimethylamine induces enhanced generation 
of superoxide radical in these cells, it seems an 
important observation that among the examined DUSP 
proteins, NDMA does not activate DUSP10 in 
neutrophils21. The lack of DUSP10 activation 
correlates with augmented cytokines and reactive 
oxygen species production36.  
There are reports that MAP kinases may stabilize, 
or through phosphorylation, lead to degradation of 
phosphatases33,34. The decreased DUSP10 expression 
observed after the inhibition of the JNK or p38 
pathway, as well as lowered DUSP16 expression after 
the inhibition of the p38 pathway in the cytoplasmic 
fraction of neutrophils exposed to NDMA indicates 
significant role of MAP kinases in the posttranslational 
regulation of these proteins in the tested cells. 
Available data indicate that DUSP10, due to its 
presence in nucleus and cytosol, may negatively 
regulate the activation of p38 MAPK in the 
cytoplasm35,36. The lack of the phosphatase leads to a 
considerable enhanced and prolonged activity of p38 
MAPK without the effect on the activity of JNK kinase 
in neutrophils. In lymphocytes DUSP10 regulates 
phosphorylation of JNK but not p38 MAPK35,37. 
However, our study showed that the activity of DUSP10 
in the cytoplasm of neutrophils exposed to NDMA 
depends on the activity of p38 and JNK kinases. 
DUSP10 and DUSP1 control the activation of MAP 
kinases, but DUSP10 regulates the early 
phosphorylation phase and DUSP1 modulates the late 
phosphorylation phase. This observation is connected 
with the different intracellular location of these 
phosphatases36-40. Our study demonstrated that the 
activity of DUSP1 in the nucleus of neutrophils 
exposed to NDMA depends on the JNK pathway. On 
the other side, the activation of DUSP16 in the 
cytoplasm is not regulated by p38. Therefore, the 
demonstrated activity of DUSP proteins as a result of 
the effect of p38 and JNK kinases may explain the 
different involvement of these kinases in the 
production of NO by PMNs subjected to the effect of 
NDMA observed in the earlier study. 
The obtained results and earlier observations 
confirm contribution of the JNK pathway in the 
activation of the p38 kinase and that this activation is 
involved in the increase of iNOS expression in PMNs 
treated with NDMA. However, our study did not 
demonstrate the effect of the p38 kinase on activation 
of JNK, which may be the result of the shorter 
incubation time with the xenobiotic. This explains the 
stronger involvement of the JNK kinase in iNOS 
activation as a result of prolonged exposure to NDMA.  
All our observations indicate that N-nitrosodimethyl-
amine activate STAT1 and STAT3 proteins in 
neutrophils. Results of this study constitute the first 
reference to the regulation of STAT protein activation 
by MAP kinases in human neutrophils exposed to this 
xenobiotic. The enhanced expression of phospho-
STAT1 and phospho-STAT3 in the cytoplasmic 
fraction of the tested proteins determined after 
inhibition of the JNK pathway indicates that this kinase 
has inhibitory role in the activation of these proteins. 
On the other hand, the decreased expression of 
phospho-STAT1 in both neutrophil fractions 
determined after inhibition of the p38 pathway 
suggests that p38 kinase has an activating effect on this 
transcription factor. Earlier studies also demonstrated 
that JAK2 kinase participates in activation of STAT1 
and STAT3 proteins. Galdiero et al.41 presented 
different results on this line. They demonstrated that in 
U937 monocytes of cell line stimulated with porins that 
STAT1 and STAT3 activation occurs solely as a result 
of the effect of p38 and JNK kinases without the 
contribution of the JAK kinases.  
Data exist on quantitative differences between the 
STAT1 and STAT3 proteins depending on the cellular 
location. The presence of STAT3 in the nucleus is not 
constant and it is constantly translocated between the 
nucleus and the cytoplasm. STAT3, contrary to 
STAT1, may accumulate in the nucleus independent of 
the phosphorylation state. Moreover, the 
phosphorylated STAT3 may also form a heterodimer 
with the phosphorylated STAT1, which may 
eventually lead to intensified nuclear accumulation of 




the transcription factor STAT3 as a result of exposure 
of cells to STAT1-activating factors42-44. This was 
further corroborated by the results of our own study, in 
which an intensified accumulation of phospho-STAT1 
and phospho-STAT3 was observed in the nucleus of 
neutrophils exposed to NDMA. 
 
Conclusion 
The obtained results indicate that N-nitroso-
dimethylamine (NDMA) activates DUSP16 and 
DUSP1 phosphatases in human neutrophils, whose 
regulation is linked with other MAP kinases. Secondly, 
the DUSP10 activation depends on both MAP kinases: 
p38 and JNK involved in iNOS regulation dependent 
NO production. Further, it reveals the role of MAP 
kinases JNK and p38 in the activation of STAT1 and 
STAT3 transcription factors involved in regulation of 
iNOS expression and NO production by human 
neutrophils treated by NDMA. The study confirms that 
MAP kinases constitute a significant role of integrator 
of the NDMA initiated signals. DUSP are positive 
regulators of MAP kinases in NDMA-induced 
signaling pathway which lead to modulation of iNOS-
dependent NO production in human neutrophils. The 
observed changes in DUSP expression in human 
neutrophils resulting from NDMA effect may lead to 
changes in other functions controlled by them, not only 
those linked to NO production. Overall, this study 
provides clarification of potential causes of impaired 
innate responses in subjects who might be exposed to 
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